Compare Invesco DB Oil Fund (DBO) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Oil Fund vs Twist Bioscience Corp — how do they compare? Invesco DB Oil Fund trades at $24.13 (market cap $255.13M), while Twist Bioscience Corp trades at $161.11 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 39.5× Invesco DB Oil Fund's market cap, and Invesco DB Oil Fund is more actively traded (562,167 versus 4,229,037). Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Oil Fund for 31 Days and Twist Bioscience Corp for 27 Days on average.
| DBO | TWST | |
|---|---|---|
Market Cap | $255.13M | $10.08B |
Volume | 562,167 | 4,229,037 |
Sector | Commodities - Energy | Health |
52-Week High | $26.35 | $205.00 |
52-Week Low | $11.98 | $25.45 |
Typical Hold Time | 31 Days | 27 Days |
Enterprise Value | — | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBO trades at $24.13, up 2.51% today amid mixed oil market signals. Technical indicators show a neutral overall signal with bearish moving averages, while oscillators remain neutral. Recent news highlights Middle East supply disruptions and OPEC+ production decisions creating volatility in energy markets. The stock faces resistance at $24 and support at $23 levels.
The outlook remains uncertain with geopolitical tensions supporting oil prices but strategic reserve releases creating downward pressure. Key risks include supply chain disruptions and regulatory challenges, while institutional sentiment appears cautious given the mixed technical signals and market volatility.
Twist Bioscience (TWST) trades at $159.78, up 2.65% today, showing strong momentum despite mixed technical signals. The company continues to demonstrate robust revenue growth, with 2025 revenue reaching $377 million, though profitability remains elusive with a -31.66% net income margin. Recent positive developments include a strategic partnership with Eli Lilly's TuneLab AI platform announced September 16, 2026, driving investor optimism about the company's AI-driven drug discovery capabilities.
While analyst consensus remains bullish with 73% buy ratings, the stock faces significant fundamental challenges including persistent cash burn and negative earnings. The current price exceeds the $145.20 consensus target, suggesting limited near-term upside. Key risks include execution challenges in achieving profitability and dependence on AI partnerships for growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco DB Oil Fund
DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.
Read more on DBO →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
